I remember coming across Virdante as a startup a few years ago and our "experts" were pretty impressed. I guess the current funding conditions were too tough for virdante. The recombinant IVIG seemed great, but maybe this for some reason was not a viable product and they couldn't convince partners to integrate yet another unproven tech into a new product? Great opportunity for a biobetter player!
Market Data 
Markets 
AI
